文献速递肝病

无创标志物(ALBI和APRI)预测慢性肝病女性的妊娠结局

Non-Invasive Markers (ALBI and APRI) Predict Pregnancy Outcomes in Women With Chronic Liver Disease.
PubMed 文献 · Am J Gastroenterol · 2019-01-01

该研究回顾了1983至2017年国王学院医院肝病门诊100例慢性肝病女性的165次妊娠,其中48例肝硬化女性的80次妊娠。肝硬化女性活产率与非肝硬化女性相似,但妊娠超过37周的比率显著更低;孕前ALBI评分较MELD更准确预测活产,APRI评分较MELD更准确预测妊娠超过37周的能力。孕前接受咨询的女性孕时肝病更稳定。

要点

  • 孕前ALBI评分预测活产的AUROC为0.741(p<0.001),优于孕前MELD。
  • 孕前APRI评分预测妊娠超过37周的AUROC为0.700(p<0.001),优于孕前MELD。
  • 孕前接受咨询的女性孕时肝病稳定比例为100% vs 86%(p=0.02)。

核心结论

  • 大多数肝硬化女性妊娠获得了成功的妊娠结局。
  • ALBI和APRI评分可预测慢性肝病女性的妊娠结局。
  • 由肝病科医生或专科产科医生进行的孕前咨询改善了该群体的患者照护。

研究设计与样本

  • 回顾性 reviewed 1983年至2017年国王学院医院肝病门诊慢性肝病女性的病历。
  • 共纳入100例慢性肝病女性的165次妊娠,其中48例肝硬化女性的80次妊娠。
  • 收集人口学、临床病史、血清学和妊娠结局信息。

主要发现

  • 肝硬化女性与非肝硬化女性活产率相似(75% vs 85%,p=0.119)。
  • 肝硬化女性妊娠超过37周的比率显著低于非肝硬化女性(45% vs 58%,p=0.033)。
  • 肝硬化女性与非肝硬化女性中位受孕年龄分别为26岁(16-44)和28岁(16-51)(p=0.015)。
  • 孕前接受咨询的女性孕时肝病稳定比例为100% vs 86%(p=0.02)。
  • 孕前ALBI评分预测活产的AUROC为0.741(p<0.001),孕前APRI评分预测妊娠超过37周的AUROC为0.700(p<0.001)。

关键数值与推荐

  • 孕前ALBI评分预测活产的AUROC为0.741(p<0.001),优于孕前MELD。
  • 孕前APRI评分预测妊娠超过37周的AUROC为0.700(p<0.001),优于孕前MELD。

临床怎么用

  • 作者认为ALBI和APRI评分可预测慢性肝病女性的妊娠结局。
  • 作者认为由肝病科医生或专科产科医生进行的孕前咨询改善了该群体的患者照护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rates of pregnancy in women with cirrhosis are increasing. Risk of hepatic decompensation during pregnancy, therefore, merits tailored obstetric and hepatology care. Prognostic markers that determine pregnancy outcomes are lacking. METHODS: Medical records of women who attended hepatology clinic at King's College Hospital with chronic liver disease (CLD) who became pregnant from 1983 to 2017 were reviewed. Information on demographics, clinical history, serology, and outcome of pregnancy was collected. RESULTS: In all, 165 pregnancies occurred in 100 women with CLD including 80 pregnancies in 48 women with cirrhosis. Median age of conception in cirrhotic and non-cirrhotic women were 26 years (16-44) and 28 years (16-51) respectively (p = 0.015). Whilst women with cirrhosis had similar live birth rate to non-cirrhotic women (75 vs. 85% p = 0.119), they were significantly less likely to proceed beyond 37 weeks gestation (45 vs. 58% p = 0.033). Women who received preconception counseling were more likely to have stable liver disease at conception (100 vs 86% p = 0.02). Compared with preconception MELD (model for end stage liver disease), preconception Albumin-Bilirubin score (ALBI) more accurately predicted live birth with an area under the receiver-operator curve (AUROC) of 0.741 (p < 0.001), and preconception AST to platelet ratio index (APRI) more accurately predicted ability to proceed beyond 37 weeks gestation with an AUROC of 0.700 (p < 0.001). CONCLUSIONS: Most women with cirrhosis who conceived achieved a successful pregnancy outcome. ALBI and APRI scores can prognosticate pregnancy outcomes in women with CLD. Preconception counseling by a hepatologist or specialist obstetrician improved patient care in this group.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Gonsalkorala ES, Cannon MD, Lim TY, et al. Non-Invasive Markers (ALBI and APRI) Predict Pregnancy Outcomes in Women With Chronic Liver Disease. Am J Gastroenterol. 2019. PMID: 29973705. doi:10.1038/s41395-018-0181-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。